Considering that treatments with GLP-1 receptor agonists were shown to improve retinal diabetic complications in animal models [14, 15], we investigated if this molecule might increase the spontaneous release of VEGF-A from ARPE-19 cells. The gene discussed is GLP1R; the disease is diabetes mellitus.